Live webcast at 11:20AM. Cultured autologous adipose derived cells......
SHANGHAI, China and PALO ALTO, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced interim 24-week clinical data from the Phase IIb trial of its ReJoinTM human adipose-derived mesenchymal progenitor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The data will be discussed by Dr. Wei (William) Cao, PhD, BM, Chief Executive Officer of Cellular Biomedicine Group at the 2015 Annual Regen Med Investor Day at the Metropolitan Club in New York City.
Dr. Cao commented, "We are very pleased to see that the KOA IIb interim data has confirmed observations from the Phase IIa trial and change in WOMAC scores in the ReJoinTM treatment arm, the primary endpoint of the Phase IIb trial, to be significantly higher than the randomized control therapy group. We remain optimistic about the efficacy of ReJoinTM treatment for KOA. With 57 million KOA patients in China, this treatment represents an opportunity to improve the quality of life for a meaningful number of patients."
ReJoinTM Phase IIb 24-week Data Analysis
The 24-week interim data shows the primary and secondary endpoints of ReJoinTM therapy group have all improved significantly compared to their baseline, which has confirmed our Phase IIa report (view report here), although only the change (47.12%) of WOMAC, the primary endpoint, is significantly higher than that of the ARTZO control group (16.32%) (p=0.017). A trend of improvement of the secondary endpoints, including cartilage MRI quantification, is observable at the 24th week. The Company expects the final results to be available at the end of 2015.